Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read More
Tag: Juluca
ViiV unveils positive data for two-drug HIV regimens
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
Read More
EU nod for ViiV/Janssen’s two-drug HIV regimen
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
Read More
Six new therapies backed for EU approval
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
US approves ViiV’s two-drug HIV regimen
ViiV Healthcare and Janssen’s Juluca has been green lighted in the US as the first two-drug regimen for some patients with HIV.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
